federal_program хобл

Список литературы

53.Regueiro C.R., Hamel M.B., Davis R.B. et al. A comparison of generalist and pulmonologist care for patients hospitalized with severe chronic obstructive pulmonary disease: resource intensity, hospital costs, and survival. SUPPORT investigators//Fm. J. Med., 1998; 105: 366–372.

54.James F. Donohue, Jan A. van Noord, Eric D. Bateman et al. A 6-month placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol//Chest, 2002; 122: 47–55.

55.Emerman C.L., Lukens T.W., Effron D. Physician estimation of FEV1 in acute exacerbation of COPD//Chest, 1994; 105: 1709–1712.

56.Emerman C.L., Cydulka R.K. Use of peak expiratory flow rate in emergency department evaluation of acute exacerbation of chronic obstructive pulmonary disease//Ann. Emerg. Med., 1996; 27: 159–163.

57.Emerman C.L., Connors A.F., Lukens T.W. et al. Relationship between arterial blood gases and spirometry in acute exacerbations of chronic obstructive pulmonary disease//Ibid., 1989; 18: 523–527.

58.Mahon J.L., Laupacis A., Hodder R.V. et al. Theophylline for irreversible chronic airflow limitation: a randomized study comparing of 1 trials to standard practice//Chest, 1999; 115: 38–48.

59.Davies L., Angus R.M. Calverley P.M. Oral cortico-steroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomized controlled trial//Lancet, 1999; 354: 456–460.

60.Niewoehner D.E., Erbland M.L., Deupree R.H. et al. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group//N. Engl. J. Med., 1999; 340: 1941–1947.

61.International Consensus Conferences in Intensive Care Medicine: noninvasive positive pressure ventilation in acute respiratory failure//Am. J. Respir. Crit. Care Med., 2001; 163: 283–291.

62.Stoller J.K., Lange P.A. Inpatient management of chronic obstructive pulmonary disease//Respir. Care Clin. N. Am., 1998; 4: 425–438.

63.The COPD Guidelines Group of the Standards of Care Committee of the BTS. BTS guidelines for the management of chronic obstructive pulmonary disease//Thorax ,1997; 52 (Suppl.) 5: S1–S28.

64.Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. National Institutes of Health; National Heart, Lung and Blood Institute, updated 2003.

65.Enright PL, Sherill DL. Reference equations for the six-minute walk in healthy adults//Am. J. Respir. Crit. Care Med., 1998; 158: 1384–1387.

66.Borg G. Psychophysical bases of perceived exertion//Med. Sci. Sport Exerc., 1982; 14: 436–447

67.Mahler D.A., Rosiello R.A., Harver A., Lentine T., McGovern J.F., Daubenspeck J.A. Comparison of clinical dyspnea ratings and psychophysical measurements on respiratory sensation in obstructive airway disease//Am. Rev. Respir. Dis., 1987; 135: 1229–1233.

68.Centers for Disease Control and Prevention. Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP)//Mortal. Morbid. Wkly Rep., 1997; 46: 1–24.

69.Szafranski W., Cukier A., Ramirez A. et al. Efficacy and safety of budesonide/formoterolin the management of chronic obstructive pulmonary disease//Eur. Respir. J.,2003; 21: 74-81.

61

Хроническая обструктивная болезнь легких

62